Rosette-forming glioneuronal tumor: an illustrative case and a systematic review. Issue 1 (9th September 2020)

• Record Type: Journal Article
• Authors: Wilson, Caleb P; Chakraborty, Arpan R; Pelargos, Panayiotis E; Shi, Helen H; Milton, Camille K; Sung, Sarah; McCoy, Tressie; Peterson, Jo Elle; Glenn, Chad A
• Is Part Of: Neuro-oncology advances. Volume 2:Issue 1(2020)
• Publication Date: 2020-09-09
• Subjects: case report -- Rosette-forming glioneuronal tumor -- systematic review; 616.99481
• DOI: 10.1093/noajnl/vdaa116
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: Rosette-forming glioneuronal tumors (RGNTs) are rare, low-grade, primary CNS tumors first described in 2002 by Komori et al. RGNTs were initially characterized as a World Health Organization (WHO) grade I tumors typically localized to the fourth ventricle. Although commonly associated with an indolent course, RGNTs have the potential for aggressive behavior. Methods: A comprehensive search of PubMed and Web of Science was performed through November 2019 using the search term "rosette-forming glioneuronal tumor." Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. English, full-text case reports and series with histopathological confirmation were included. Patient demographics, presentations, MRI features, tumor location, treatment, and follow-up of all 130 cases were extracted. Results: A 19-year-old man with a history of epilepsy and autism presented with acute hydrocephalus. MRI scans from 2013 to 2016 demonstrated unchanged abnormal areas of cortex in the left temporal lobe with extension into the deep gray-white matter. On presentation to our clinic in 2019, the lesion demonstrated significant progression. The patient's tumor was identified as RGNT, WHO grade I. One hundred thirty patients were identified across 80 studies. Conclusion: RGNT has potential to transform from an indolent tumor to a tumor with more aggressive behavior. The results of our systematic review provide insight into the natural history and treatment outcomes of these rare tumors.